|References 1–20 |
|1. Lieberman DA, et al. Prevalence of colon polyps detected by colonoscopy screening in asymptomatic black and white patients. JAMA. 2008;300:1459–61. |
2. Agrawal S,, et al. Colorectal cancer in African Americans. Am J Gastroenterol. 2005;100:515–23.
3. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22;191–97.
4. Okabayashi K,, et al. Body mass index category as a risk factor for colorectal adenomas: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107:1175–85.
5. Henderson TO,, et al. Secondary gastrointestinal malignancies in childhood cancer survivors: a cohort study. Ann Intern Med. 2012;156:757–66.
6. Rodriquez, AM, Kuo YF, Goodwin JS. Risk of colorectal cancer among long-term cervical cancer survivors. Medical Oncology. 2014;31:943–52.
7. Ashktorab H, et al. Racial disparity in gastrointestinal cancer risk. Gastroenterology. 2017;153: 910–23.
8. Sheffield KM, et al. Potentially inappropriate screening colonoscopy in Medicare patients. JAMA. 2013;173:542–50.
9. Torke AM, et al. Older adults and forgoing cancer screening. JAMA. 2013;173:526–31.
10. Day LW, et al. Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointest Endosc. 2011;74:885–96.
|11. Collins JF, et al. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 2005;142:81–5. |
12. Markowitz GS, et al. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol. 2005;16:3389–96.
13. Khurana A, et al. The effects of oral sodium phosphate drug products on renal function in adults undergoing bowel endoscopy. Arch Intern Med. 2008:168(6):593–97..
14. Heher EC, et al. Adverse renal and metabolic effects associated with oral sodium phosphate bowel preparation. Clin J Am Soc Nephrol. 2008;3:1494–1503.
15. Gurudu SR, et al. Increased adenoma detection rate with system-wide implementation of a split-dose preparation for colonoscopy. Gastrointest Endosc. 2012;76:603–8.
16. Burt RW. Colon Cancer Screening. Gastroenterology. 2000;119:837–53.
17. Graff RE, et al. Familial risk and heritability of colorectal cancer in the Nordic Twin Study of Cancer. Clin Gastroenterol Hepatol. 2017;1256–64.
18. Strum WB. Colorectal adenomas. NEJM. 2017;374:1065–75.
19. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med. 2003;138:560–70.
20. Hampel H, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). NEJM. 2005;352:1851–60.
| References 21–40 |
|21. Lubbe SJ, et al. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol. 2009;27:3975–80. |
22. Jasperson KW, et al. Hereditary and familial colon cancer. Gastroenterology. 2010;138:2044–58.
23. Bernstein CN, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854–62.
24. Beaugerie L, et al. Risk of colorectal high grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145:166–75.
25. Farraye FA, et al. AGA Technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746–74.
26. Farraye FA, et al. AGA Medical Position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738–45.
27. Nishihara R, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. NEJM. 2013;369:1095–105.
28. Doubeni CA., et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average risk adults. Ann Intern Med. 2013;158(5 Part 1):312–20.
29. Shaukat A, et al. Long-term mortality after screening for colorectal cancer. NEJM. 2013;369:1106–14.
30. Levin TR, et al. Colorectal-cancer screening-coming of age. NEJM. 2013:1164–66.
|31. Lai EJ, et al. The Boston Bowel Preparation Scale: A valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc. 2009;69(3 Pt 2):620–25 . |
32. Whitlock EP, et al. Screening for colorectal cancer: A targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:638–58.
33. Zauber AG, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:659–69.
34. Brenner H, et al. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med. 2011;154:22–30.
35. USPSTF. Screening for colorectal cancer: recommendation statement. Ann Intern Med. 2008;149:680–82.
36. Zauber AG, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. NEJM. 2012;366:687–96.
37. Lieberman DA, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on colorectal cancer. Gastroenterology. 2012;143:844–57.
38. Lin JS, et al. Screening for colorectal cancer. updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016;315:2576–94.
39. Rex, DK, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc. 2017;86:18–33.
40. Lieberman DA, et al. Screening for colorectal cancer and evolving issues for physicians and patients: a review. JAMA. 2016;316(20):2135–45.
|References 41–60 |
|41. Percac-Lima S, et al. Diagnostic evaluation of patients presenting to primary care with rectal bleeding. J Gen Intern Med. 2018;33(4):415–42. |
42. Siegel RL, et al. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2009;18:1695– 98.
43. Holowatyj AN, et al. Racial/ethnic disparities in survival among patients with young-onset colorectal cancer. J Clin Oncol. 2016;34:2148–56.
44. Meyer JE, et al. Increasing incidence of rectal cancer in patients aged younger than 40 years. Cancer. 2010;116:4354–59.
45. Chen FW, et al. Advanced stage colorectal cancer in persons younger than 50 years not associated with longer duration of symptoms to time to diagnosis. Clin Gastroenterol Hepatol. 2017;15:728–37.
46. Shields HM, et al. Disparities in evaluation of patients with rectal bleeding 40 years of age and older. Clin Gastroenterol Hepatol. 2014;12:669–75.
47. Karsenti D, et al. Adenoma detection rate according to age: colonoscopy screening should start at 45 years old, Presented at the 25th UEG Week Barcelona, October 30, 2017.
48. Murphy CC, et al. Young-onset colorectal cancer: earlier diagnoses or increasing disease burden? Gastroenterology. 2017;152(8):1809–12.
49. Kaminski MF, et al. Quality indicators for colonoscopy and the risk of interval cancer. NEJM. 2010;362:1795–1803.
50. Robertson D, et al. Using the results of a baseline and a surveillance colonoscopy to predict recurrent adenomas with high-risk characteristics. Ann Intern Med. 2009;151:103–9.
|51. Baxter NM, et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med. 2009;150:1–8. |
52. Ransohoff DF, et al. How much does colonoscopy reduce colon cancer mortality? Ann Intern Med. 2009;150:50–2.
53. Morikawa T, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422–28.
54. Liles EG, et al. Change to FIT increased CRC screening rates: Evaluation of a US screening outreach program. Am J Manag Care. 2012;18: 588–95.
55. Murphy CC, et al. Underuse and overuse of colonoscopy for repeat screening and surveillance in the Veterans Health Administration. Clin Gastroenterol Hepatol. 2016;14(3):436–44.
56. Qunitero E, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. NEJM. 2012;366:697–706.
57. Inadomi JM, et al. Adherence to colorectal cancer screening. A randomized clinical trial of competing strategies. JAMA. 2012;172:575–82.
58. Robertson DJ, et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the U.S. Multi-society Task Force on Colorectal Cancer. Gastrointest Endosc. 2016;85:2–21
59. Akram A, et al. Replacing the guaiac fecal occult blood test with the fecal immunochemical test increases proportion of individuals screened in a large healthcare setting. Clin Gastroenterol Hepatol. 2017;15:1265–70.
60. van der Vlugt M, et al. Interval colorectal cancer incidence among subjects undergoing multiple rounds of fecal immunochemical testing.
|References 61–70 |
|61. Jensen CD, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med. 2016;164:456–63. |
62. Lee JK, et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160:171–81.
63. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. NEJM. 2001;345:555–60.
64. Levi Z, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007;146:244–55.
65. Cash BD, et al. Clinical use of CT colonography for colorectal cancer screening in military training facilities and potential impact on HEDIS measures. J Am Coll Radiol. 2013;10:30–6.
|66. Imperiale TF, et al. Multitarget stool DNA testing for colorectal-cancer screening. NEJM. 2014;370:1287–97. |
67. Lieberman DA, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer: Veterans Affairs Cooperative Study 380. NEJM. 2000;343:162–68.
68. Imperiale TF, et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. NEJM. 2000;343:169–74.
69. Kolb JM, et al. Detection, diagnosis and resection of sessile serrated adenomas and polyps. Gastroenterology. 2017;153:646–48.
70. Kahi CJ, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016;150:758–68.
|References 71–82 |
| 71. Rex DK, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology. 1997;112:24–8. |
72. Aslinia F, et al. Quality assessment of colonoscopic cecal intubation: an analysis of 6 years of continuous practice at a university hospital. Am J Gastroenterol. 2006;101:721–31.
73. Lee RH. Quality colonoscopy: a matter of time, technique or technology? World J Gastroenterol. 2013;19:1517–22.
74. Brenner H, et al. Role of colonoscopy and polyp characteristics in colorectal cancer after colonoscopic polyp detection. Ann Intern Med. 2012;157:225–32.
75. Rex DK, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107:1315–29.
76. Pohl H, et al. Incomplete polyp resection during colonoscopy: results of the complete adenoma resection (CARE) study. Gastroenterology. 2013;144:74–80.
|77. National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2012 Panel Members Colorectal Cancer Screening. NCCN.org. |
78. Kahi CJ, Rex DK. Why we should CARE about polypectomy technique. Gastroenterology. 2013;144:16–8.
79. Iannone A, et al. Chromoendoscopy for surveillance in ulcerative colitis and crohn’s disease: a systematic review of randomized trials. Clin Gastroenterol Hepatol. 2017;15:1684–97.
80. Giardiello FM, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014;109:1159–79.
81. Umar A, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–68.
82. Bresalier RS. Colorectal Cancer. In: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Ninth Edition. Eds. Mark Feldman, Lawrence S. Friedman, Lawrence J. Brandt. Philadelphia, Saunders Elsevier. 2010. p. 2208.